AstraZeneca plc had the distinct but risky opportunity of providing those watching biotechnology with the first glimpse of data from a Phase III trial of an endothelial growth factor receptor inhibitor in combination with other cancer treatments. That honor proffered unfavorable results that Monday helped drag down a sizable chunk of the sector's stocks. (BioWorld Today)

AstraZeneca plc had the distinct but risky opportunity of providing those watching biotechnology with the first glimpse of data from a Phase III trial of an endothelial growth factor receptor inhibitor in combination with other cancer treatments. That honor proffered unfavorable results that Monday helped drag down a sizable chunk of the sector's stocks. (BioWorld Today)

In a market that is fiercely devaluing companies and following a deflating non-approvable letter from the FDA for Risperdal, Alkermes Inc. said after the markets closed it and Reliant Pharmaceuticals LLC are nixing their planned merger that was valued at $934 million when it was announced in March. (BioWorld Today)

In a market that is fiercely devaluing companies and following a deflating non-approvable letter from the FDA for Risperdal, Alkermes Inc. said after the markets closed it and Reliant Pharmaceuticals LLC are nixing their planned merger that was valued at $934 million when it was announced in March. (BioWorld Today)